Blueprint Medicines Presents Foundational Preclinical Data Supporting the Development of BLU-782, a Highly Selective ALK2 Inhibitor, for the Treatment of Patients with Fibrodysplasia Ossif...
Blueprint Medicines Corporation (BPMC)
Last blueprint medicines corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
blueprintmedicines.com
Company Research
Source: PR Newswire
Impact Snapshot
Event Time:
BPMC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BPMC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BPMC alerts
High impacting Blueprint Medicines Corporation news events
Weekly update
A roundup of the hottest topics
BPMC
News
- Blueprint Medicines Co. (<a href="https://www.marketbeat.com/stocks/NASDAQ/BPMC/price-target/">NASDAQ: BPMC</a>) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
- Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)PR Newswire
- Blueprint Medicines Co. (<a href="https://www.marketbeat.com/stocks/NASDAQ/BPMC/price-target/">NASDAQ: BPMC</a>) had its price target lowered by analysts at Robert W. Baird from $123.00 to $96.00.MarketBeat
- Blueprint Medicines Corporation (BPMC) CEO Kate Haviland On Q1 2022 Results - Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Blueprint Medicines Reports First Quarter 2022 ResultsPR Newswire
BPMC
Earnings
- 5/3/22 - Beat
BPMC
Sec Filings
- 5/18/22 - Form 4
- 5/10/22 - Form SC
- 5/3/22 - Form 10-Q
- BPMC's page on the SEC website